The goal of this clinical trial is to determine the safest and most effective dose of Modakafusp Alfa when given by itself and when combined with Dexamethasone to patients who have relapsed / refractory Multiple Myeloma.
SparkCures ID | 907 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 336 Patients |
Treatments |
|
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
For Parts 1 and 2:
For Part 3:
Exclusion Criteria:
For Parts 1 and 2:
For Part 3:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersSparkCures is working closely with Takeda Oncology to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors